Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.15829 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Renal microangiopathy induced by lenvatinib in hepatocellular carcinoma: a case report and literature review.
Front Pharmacol
November 2024
Department of Nephrology, Shanghai Changzheng Hospital, Second Military Medical University (Naval Medical University), Shanghai, China.
Lenvatinib, a multi-target inhibitor of receptor tyrosine kinases, has been increasingly used in the treatment of advanced hepatocellular carcinoma (HCC). However, its association with renal adverse effects, including proteinuria and renal microvascular complications, was not fully understood in HCC patients. We reported a case of a 68-year-old male with a history of hypertension, diabetes mellitus, and hepatitis C virus (HCV) infection, diagnosed with primary HCC in 2015.
View Article and Find Full Text PDFHand Foot Syndrome Induced by Lenvatinib - A Case Report.
Curr Drug Saf
March 2024
Department of Radiotherapy, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Introduction: Hand-Foot Syndrome (HFS), also known as palmar-plantar erythrodysesthesia, is a common reaction to Tyrosine Kinase Inhibitors ( TKIs), which can often lead to discontinuation of the drug. Lenvatinib is a recently approved drug for the treatment of endometrial carcinoma, which has been proven to provide a better overall survival rate and longer duration of progression-free survival among patients with advanced endometrial cancer. Herein, we have reported a case of carcinoma endometrium with metastasis who had to discontinue the use of lenvatinib due to the adverse drug reaction.
View Article and Find Full Text PDFRectal ulcer associated with lenvatinib 15 years after definitive radiotherapy for prostate cancer: A case report.
Oncol Lett
January 2024
Department of Radiology, Kawasaki Medical School, Kurashiki, Okayama 701-0192, Japan.
Lenvatinib is a multi-kinase inhibitor that blocks vascular endothelial growth factor, fibroblast growth factor and platelet-derived growth factor receptors. The present study describes a case of rectal ulceration triggered by lenvatinib treatment for hepatocellular carcinoma 15 years after definitive radiotherapy for prostate cancer. A 58-year-old man underwent definitive external beam radiotherapy and high-dose-rate brachytherapy for prostate cancer.
View Article and Find Full Text PDFLenvatinib-Induced Tumor Lysis Syndrome in Advanced Hepatocellular Carcinoma.
ACG Case Rep J
September 2023
Department of Gastroenterology, Dayanand Medical College & Hospital, Ludhiana, Punjab, India.
This case report describes a 48-year-old man with hepatocellular carcinoma who developed tumor lysis syndrome (TLS) after 7 days of starting lenvatinib therapy. The patient was hospitalized and received appropriate interventions, including aggressive hydration, allopurinol, rasburicase, and electrolyte management. The patient's condition improved, and he was eventually discharged from the hospital.
View Article and Find Full Text PDFLenvatinib-induced pyoderma gangrenosum in a patient with hepatocellular carcinoma: A case report.
J Dermatol
February 2024
Department of Dermatology, Tokyo Medical University Ibaraki Medical Center, Ami, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!